Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors
Authors
Keywords
-
Journal
Nature Communications
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-31
DOI
10.1038/s41467-021-22311-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Platelet activation markers in evaluation of thrombotic risk factors in various clinical settings
- (2019) Meganathan Kannan et al. BLOOD REVIEWS
- The Role of Toll-Like Receptors in Oncotherapy
- (2019) Caiqi Liu et al. ONCOLOGY RESEARCH
- Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model
- (2019) Jayanth S. Shankara Narayanan et al. Cancer Immunology Research
- Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
- (2019) Stefanie R. Mullins et al. Journal for ImmunoTherapy of Cancer
- Co-delivery of immunomodulators in biodegradable nanoparticles improves therapeutic efficacy of cancer vaccines
- (2019) C.G. Da Silva et al. BIOMATERIALS
- The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer
- (2019) Katherine A. Michaelis et al. Nature Communications
- Cell Membrane Coating Nanotechnology
- (2018) Ronnie H. Fang et al. ADVANCED MATERIALS
- Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents
- (2018) Xiaohong Ruby Xu et al. BLOOD
- The Platelet Lifeline to Cancer: Challenges and Opportunities
- (2018) Monika Haemmerle et al. CANCER CELL
- Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy
- (2018) Naoto Nishii et al. Oncotarget
- TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy
- (2018) Christopher B. Rodell et al. Nature Biomedical Engineering
- Targeting Toll-Like Receptors for Cancer Therapy
- (2018) Marc J. Braunstein et al. Targeted Oncology
- T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection
- (2018) Jonathan A. Trujillo et al. Cancer Immunology Research
- A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells
- (2017) E J Cheadle et al. LEUKEMIA
- T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity
- (2017) Daniela Schmid et al. Nature Communications
- Anti-tumor Activity of Toll-Like Receptor 7 Agonists
- (2017) Huju Chi et al. Frontiers in Pharmacology
- Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors
- (2017) Yingjie Nie et al. Scientific Reports
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade
- (2015) Elizabeth Buchbinder et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
- (2015) Lieping Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Nanoparticle biointerfacing by platelet membrane cloaking
- (2015) Che-Ming J. Hu et al. NATURE
- Targeting the Effector Site with IFN- -Inducing TLR Ligands Reactivates Tumor-Resident CD8 T Cell Responses to Eradicate Established Solid Tumors
- (2014) A. J. Currie et al. JOURNAL OF IMMUNOLOGY
- Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation
- (2014) Manisha Singh et al. JOURNAL OF IMMUNOLOGY
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Trial Watch
- (2014) Fernando Aranda et al. OncoImmunology
- Platelet activation: a link between psoriasisper seand subclinical atherosclerosis - a case-control study
- (2013) H.M.A. Saleh et al. BRITISH JOURNAL OF DERMATOLOGY
- The use of Toll-like receptor 7/8 agonists as vaccine adjuvants
- (2013) John P Vasilakos et al. Expert Review of Vaccines
- Toll-Like Receptors in Antiviral Innate Immunity
- (2013) Sandra N. Lester et al. JOURNAL OF MOLECULAR BIOLOGY
- Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles
- (2013) Brian T. Luk et al. Nanoscale
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma
- (2012) S. J. Dovedi et al. BLOOD
- Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells
- (2012) Barbara Drobits et al. JOURNAL OF CLINICAL INVESTIGATION
- Development of immune memory to glial brain tumors after tumor regression induced by immunotherapeutic Toll-like receptor 7/8 activation
- (2012) Apostolis Stathopoulos et al. OncoImmunology
- Increased levels of platelet activation markers are positively associated with carotid wall thickness and other atherosclerotic risk factors in obese patients
- (2011) Bela Nagy et al. THROMBOSIS AND HAEMOSTASIS
- Toll-Like Receptors: Cost or Benefit for Cancer?
- (2010) T. Matijevic et al. CURRENT PHARMACEUTICAL DESIGN
- Activated T–cell-mediated Immunotherapy With a Chimeric Receptor Against CD38 in B-cell Non-Hodgkin Lymphoma
- (2009) Keichiro Mihara et al. JOURNAL OF IMMUNOTHERAPY
- An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma
- (2008) R. Dummer et al. CLINICAL CANCER RESEARCH
- TLR7 and TLR8 as targets in cancer therapy
- (2008) M P Schön et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More